TREA

98472315 - LAGIMMU

Follow

Information

  • Trademark
  • 98472315
  • Serial Number
    98472315
  • Filing Date
    March 28, 2024
    a year ago
  • Transaction Date
    April 15, 2025
    a month ago
  • Status Date
    April 14, 2025
    a month ago
  • Location Date
    April 14, 2025
    a month ago
  • Status Code
    602
  • Current Location
    TMO LAW OFFICE 113
    Employee Name
    BRYANT, ALEXANDRIA
  • Attorney Docket Number
    00163437-US
    Attorney Name
    Marilyn F. Kelly
    Law Office Assigned Location Code
    M40
  • Owners
Information
Mark Drawing Code
4
Mark Identification
LAGIMMU
Case File Statements
  • GS0051: Pharmaceutical preparations for human use for the treatment and prevention of obesity, incontinence, cardiovascular diseases, central nervous system diseases and disorders, metabolic disorders, stroke, cancer, inflammation and inflammatory diseases, respiratory and infectious diseases, auto-immune diseases, solid organ transplant rejection, beta thalassemia and myelodysplastic syndromes, myeloproliferative diseases, myelofibrosis, leukemia, lymphoma, multiple myeloma, autoinflammatory disease, blood disease, tumors, multiple sclerosis, ulcerative colitis, arthritis, and musculoskeletal and skin diseases; Pharmaceutical preparations for human use, namely, antibiotics, anti-fungals, anti-virals, immunosuppressants, pharmaceutical antibodies, immunotherapies for the treatment of cancer, cytokine inhibitory drugs; Pharmaceutical preparations for human use that modulate the immune system; Pharmaceutical and biological preparations for human use for immunotherapy, namely T Cell therapy; Pharmaceutical preparations for human use, namely, stem cells for medical or clinical use; Pharmaceutical preparations for human use for the treatment or prevention of covid-19, coronavirus disease, and respiratory diseases and disorders; Pharmaceutical preparations for human use, namely, antivirals for treatment or prevention of covid-19, coronavirus disease, and respiratory diseases and disorders; Pharmaceutical preparations for human use, namely, monoclonal antibodies for medical use; pharmaceutical preparations for the treatment of neuropsychiatric disorders; therapeutic radiopharmaceutical preparations for the treatment of cancer and solid tumors; diagnostic radiopharmaceutical preparations; diagnostic agents, preparations and substances for medical purposes; radiopharmaceutical imaging and detection agents for diagnosing and monitoring cancer; radio-isotope markers for therapeutic or diagnostic use.
Case File Event Statements
  • 3/28/2024 - a year ago
    1 - NEW APPLICATION ENTERED Type: NWAP
  • 8/6/2024 - 9 months ago
    3 - ASSIGNED TO EXAMINER Type: DOCK
  • 8/7/2024 - 9 months ago
    4 - NON-FINAL ACTION WRITTEN Type: CNRT
  • 7/8/2024 - 10 months ago
    2 - NEW APPLICATION OFFICE SUPPLIED DATA ENTERED Type: NWOS
  • 8/7/2024 - 9 months ago
    6 - NOTIFICATION OF NON-FINAL ACTION E-MAILED Type: GNRN
  • 8/7/2024 - 9 months ago
    5 - NON-FINAL ACTION E-MAILED Type: GNRT
  • 11/1/2024 - 6 months ago
    9 - TEAS/EMAIL CORRESPONDENCE ENTERED Type: TEME
  • 11/1/2024 - 6 months ago
    8 - CORRESPONDENCE RECEIVED IN LAW OFFICE Type: CRFA
  • 11/1/2024 - 6 months ago
    7 - TEAS RESPONSE TO OFFICE ACTION RECEIVED Type: TROA
  • 12/27/2024 - 4 months ago
    10 - FINAL REFUSAL WRITTEN Type: CNFR
  • 12/27/2024 - 4 months ago
    12 - NOTIFICATION OF FINAL REFUSAL EMAILED Type: GNFN
  • 12/27/2024 - 4 months ago
    11 - FINAL REFUSAL E-MAILED Type: GNFR
  • 4/14/2025 - a month ago
    13 - ABANDONMENT - FAILURE TO RESPOND OR LATE RESPONSE Type: ABN2
  • 4/14/2025 - a month ago
    14 - ABANDONMENT NOTICE E-MAILED - FAILURE TO RESPOND Type: MAB2